Aptose reports CG-806 data in patients with chronic lymphocytic leukemia
Aptose Biosciences released highlights from a corporate event and clinical update held at the American Society of Hematology Annual Meeting. The company said, "As the first clinical data from CG-806 in patients with chronic lymphocytic leukemia have begun to emerge, Drs. Howell, Bejar, and Druker highlighted the consistency between the drug's robust preclinical profile and the early clinical observations on safety, tolerability, pharmacokinetics, and activity. William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose also provided a corporate update on the clinical activities of CG-806, Aptose's highly potent pan-FLT3/pan-BTK inhibitor." Key findings from dose levels 1 and 2 of CG-806 in heavily pretreated R/R chronic lymphocytic leukemia patients: "CG-806's safety profile remains clean; no unexpected toxicities have been observed to date...Early evidence of clinical response has already been observed in a R/R CLL patient at dose level 2...Evidence of Bruton's tyrosine kinase target engagement...Meaningful oral absorption and predictable pharmacokinetic profile...Exposures are likely therapeutic for acute myeloid leukemia patients." The company added APTO-253 is "demonstrating safety and MYC target engagement in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory AML or high-risk myelodysplastic syndrome." It continues to escalate dosing with both assets, as all current dose cohorts to date have exhibited favorable safety profiles and evidence of target engagement.